Ropinirole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ropinirole: From [Indication Not Specified] to Attention-Deficit/Hyperactivity Disorder
One-Sentence Summary
Ropinirole is a non-ergot D2/D3 receptor selective dopamine agonist; original indication data was not provided in this evidence pack. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), with 0 clinical trials and 8 publications currently supporting this direction — most of the literature describes RLS-ADHD comorbidity rather than direct treatment evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no license records available) |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ropinirole is a non-ergot dopamine receptor agonist with selectivity for D2/D3 receptors. ADHD pathophysiology involves reduced dopaminergic transmission in the prefrontal-striatal circuit, and in theory a dopamine agonist could increase dopaminergic tone in this pathway. However, the mechanism differs fundamentally from currently approved ADHD medications: methylphenidate and amphetamine-class drugs act by inhibiting/promoting release via the dopamine transporter (DAT), while atomoxetine inhibits the norepinephrine transporter (NET). Direct D2/D3 receptor agonism carries a theoretical risk of receptor down-regulation with repeated dosing and of triggering psychiatric symptoms, making the mechanistic plausibility moderate-to-low.
Most of the supporting literature describes the clinical co-occurrence of Restless Legs Syndrome (RLS) and ADHD — including a single pediatric case report where ropinirole improved both RLS and ADHD symptoms — rather than controlled treatment trials targeting ADHD directly. Detailed mechanism-of-action data for ropinirole beyond D2/D3 agonism, and confirmed original approved indications, were not available in this evidence pack.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15866437 | 2005 | Case Report | Pediatric Neurology | 6-year-old with ADHD and RLS showed significant improvement in both ADHD symptoms and sleep problems after switching to ropinirole |
| 16218085 | 2005 | Review | Sleep | Reviews the RLS-ADHD association, hypothetical shared mechanisms, and rationale for common pharmacologic treatment |
| 18656214 | 2008 | Review | Revue Neurologique | General review of RLS pathophysiology and clinical features, including comorbidity discussion |
| 34182128 | 2021 | In vitro/Basic | Pharmacological Research | Studies D4 receptor-α2A adrenoceptor heteromerization relevant to ADHD and impulsive-control disorders |
| 24992083 | 2014 | RCT (Parkinson’s disease population) | Clinical Neuropharmacology | Comparison of piribedil vs. pramipexole/ropinirole on vigilance in PD patients with daytime sleepiness — not ADHD-specific |
| 30950895 | 2019 | Case series | Cornea | Describes corneal edema associated with systemic dopaminergic agents — safety-relevant, not efficacy evidence |
| 17483695 | 2007 | Animal model | J Neuropathol Exp Neurol | Iron-deprived A11-lesioned mouse model proposed for RLS, involving dopaminergic and iron pathways |
| 30460371 | 2019 | Case report | Acta Dermato-Venereologica | Reports treatment-induced delusions of infestation associated with elevated brain dopamine levels |
US Market Information
Currently no license/approval records available in the evidence pack — market status is listed as Not Marketed with 0 total authorizations.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic plausibility for ADHD is only moderate-to-low, since ropinirole’s full D2/D3 agonism differs from validated ADHD drug mechanisms and carries a theoretical risk of exacerbating psychiatric symptoms. There are no clinical trials, and the literature consists mainly of comorbidity reviews and a single pediatric case report rather than controlled efficacy data — insufficient to support advancement at this time.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (currently a blocking data gap for safety screening)
- Confirmed mechanism-of-action and original approved indication documentation from DrugBank or regulatory sources
- Controlled clinical studies (ideally RCTs) directly evaluating ropinirole for ADHD symptoms
- Psychiatric safety monitoring plan, given known risk of dopaminergic agonist-induced psychosis/delusions in other populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.